Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — H1 FY2023 Earnings Presentation
22 slides from Aft Pharmaceuticals's earnings presentation, Nov 24, 2022
Slide 1: Investor Presentation 1H FY2023
For personal use only INVESTOR PRESENTATION 1H FY2023 24 NOVEMBER 2022
Slide 2: Important Notice
Important Notice For personal use only This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of the performance of AFT for the half year to 30 September 2022. It is not prepared for any other purpose and must not be provided to any person other tha
Slide 3: Growing Globally From a Strong Australasian Core
Growing Globally From a Strong Australasian Core For personal use only Rest of the World: AFT developed IP commercialised in Asia: A broad range of products 51 countries (including ANZ) sold and agreements in more than Australasia: 150+ products across seven therapeutic areas 100 territories distrib
Slide 4: 1H FY2023 Highlights: Delivering Strong Organic Growth
1H FY2023 Highlights: Delivering Strong Organic Growth For personal use only • Half-year operating revenue $65.8 million, up 18.4% from $55.5 million lifted by new products launches and organic growth – with revenue from product sales and royalty income up 30%. • Operating profits $3.5 million, down
Slide 5: Australia: Sales Accelerating Following Recent Product Launches
Australia: Sales Accelerating Following Recent Product Launches For personal use only • Sales in Australia accelerated to $36.1 million, up 24% from $29.2 million, benefiting from normalisation of trading to pre-COVID levels and 11 product launches. • OTC channel the standout performer, up 36.9% to
Slide 6: New Zealand: Strong Organic Growth Across All Channels
New Zealand: Strong Organic Growth Across All Channels For personal use only • Revenue in New Zealand grew across all channels rising to $21.3 million, up 35% from $15.8 million. • Revenue growth lifted by strong post Covid organic product growth, a 28.5% increase in the OTC business and a strong co
Slide 7: Driving Australasian Growth With New Products and Salesforce Investment
Driving Australasian Growth With New Products and Salesforce Investment For personal use only • Portfolio of product launches for our Australasian business. • During 1H FY23, 5 OTC products, including Maxigesic hot drink sachets, launched, and 6 hospital products • During 2H FY23, an additional 14 O
Slide 8: Asia: McPherson's Distribution Partnership Lifts Asian Sales
Asia: McPherson’s Distribution Partnership Lifts Asian Sales For personal use only • Sales in Asia rose to $3.7 million, up 26.1% from $2.9 million, driven by a more than doubling (115%) of sales in the OTC business, a result of the agreement with ASX-listed McPherson's to drive OTC sales in Singapo
Slide 9: International: Strong Organic Growth Offset by Lower Licence Income
International: Strong Organic Growth Offset by Lower Licence Income For personal use only INTERNATIONAL REVENUE COUNTRIES WHERE MAXIGESIC IS SOLD AND ORDERED 14 $13.1 80 73 12 70 63 $9.9 $5.5 60 10 $9.1 50 46 43 COUNTRIES 8 $NZM $5.9 40 6 28 30 4 $3.6 20 $7.6 20 2 $4.7 7 9 10 4 2 3 0 FY2018 FY2019 F
Slide 10: Maxigesic Global Update
Maxigesic Global Update A US$59 billion market1 For personal use only 1 www.ex pertmark etres earc h.com/reports/anal gesi c s-market 10
Slide 11: Investing in a Strong Research and Development Pipeline
Investing in a Strong Research and Development Pipeline For personal use only AFT’s positive cashflows position the company well to undertake and secure research and development projects either alone or in partnership with others. NasoSURF PROJECT KW Ultrasonic nasal mesh nebuliser used for the Gast
Slide 12: Operating Profit Lower on Reduced License Income
Operating Profit Lower on Reduced License Income For personal use only Revenue Revenue % % • Excluding licensing income, operating NZ$'000's for the six months to 30 September 2022 2021 profit increased to $3.4m from $0.7m. Revenue 65,750 55,513 • Gross profit margin decline of 4.5 Gross profit 28,6
Slide 13: Cash Flow: AFT Remains Well Funded as Debt Reduction Continues
Cash Flow: AFT Remains Well Funded as Debt Reduction Continues For personal use only NZ$'000's period ended 30 September 2022 2021 • High inventory day levels Net cash from operating activities 5,983 6,826 maintained and new launch Net cash used in investing activities (4,853) (2,770) inventory Net
Slide 14: Balance Sheet: Well Funded, Net Debt Within Range
Balance Sheet: Well Funded, Net Debt Within Range For personal use only NZ$'000's period ended 30 September 2022 2021 • Net debt of $29.3m reduced from Current assets 68,358 60,280 $32.6m a year ago Cash 8,795 5,907 Non-current assets 49,150 39,521 • Net debt at half year ahead of 1X EBITDA target b
Slide 15: Outlook: product launches to support continued growth
Outlook: product launches to support continued growth For personal use only • We see a stronger second half. We expect the result for the full year to be even more skewed to the second half than normal, due to the high number of planned launches in 2H FY23. • Due to our higher investment in Sales &
Slide 16: Questions
For personal use only QUESTIONS
Slide 17: www.aftpharm.com
For personal use only www.aftpharm.com
Slide 18: Appendix 1: Australasian Product Portfolio
Appendix 1: Australasian Product Portfolio For personal use only AFT has the #1 selling product (Maxigesic) in the Australian para-ibu1 combo pain relief. AFT’s portfolio includes a combination of over 150 proprietary, branded and generic products which address the following therapeutic areas: Pain
Slide 19: Appendix 2: AFT Global Product Portfolio
Appendix 2: AFT Global Product Portfolio For personal use only AFT is building the global presence of its proprietary and patented products through its network of licensees and distributors. It continues the development of its portfolio of repurposed medicines: Maxigesic1, Pascomer, NasoSURF, Crysta
Slide 20: Appendix 3: History of AFT Pharmaceuticals
Appendix 3: History of AFT Pharmaceuticals For personal use only AFT was founded 23 years ago by Dr Hartley and Marree Atkinson. Since then AFT has remained an Atkinson-family controlled business and has grown organically into Australia and internationally The 2015 IPO raised funds to pursue a more
Slide 21: Appendix 4: ESG Focusing on What Matters
Appendix 4: ESG Focusing on What Matters For personal use only Our Mission: Working to Improve Your Health AFT is committed to enhancing the health and wellbeing of people and communities in the markets we serve and operating a sustainable business. AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH
Slide 22: For More Information
For personal use only www.aftpharm.com FOR MORE INFORMATION Dr Hartley Atkinson Managing Director Email: hartley@aftpharm.com Malcolm Tubby Chief Financial Officer Email: malcolm@aftpharm.com AFT Pharmaceuticals Limited Level 1, 129 Hurstmere Road Takapuna, Auckland 0622 New Zealand
AFT Pharmaceuticals — H1 FY2023 Earnings Presentation on 6ix